All In Biotech

NDA 021110 · Pf Prism Cv

Rapamune

Sirolimus · Oral · mTOR Inhibitor Immunosuppressant; Kinase Inhibitor

Breakthrough therapyOrphan

Last checked: Nov 20, 2026Latest source record: Aug 22, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Aug 25, 2000

Approved uses

7

Original approval plus efficacy supplements

Registered trials

1,853

224 Phase 3, 143 recruiting

FAERS reports

13,477

11,670 serious, 2,174 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: IMMUNOSUPPRESSION, USE IS NOT RECOMMENDED IN LIVER OR LUNG TRANSPLANT PATIENTS • Increased susceptibility to infection and the possible development of lymphoma and other malignancies may result from immunosuppression Increased susceptibility to infection and the possible development of lymphoma may result from immunosuppression. Only physicians experienced in immunosuppressive therapy and management of renal transplant patients should use sirolimus for prophylaxis of organ rejection in patients receiving renal transplants. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient [ see Warnings and Precautions (5.1) ] . • The safety and efficacy of sirolimus as...

What it is approved for

From the label in effect Mar 26, 2026.

Sirolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in patients aged ≥13 years receiving renal transplants: - Patients at low- to moderate-immunologic risk: Use initially with cyclosporine (CsA) and corticosteroids. CsA withdrawal is recommended 2–4 months after transplantation ( 1.1 ). - Patients at high-immunologic risk: Use in combination with CsA and corticosteroids for the first 12 months following transplantation ( 1.1 ). Safety and efficacy of CsA withdrawal has not been established in high risk patients ( 1.1 , 1.2 , 14.3 ). Sirolimus is an mTOR inhibitor indicated for the treatment of patients with lymphangioleiomyomatosis ( 1.3 ). 1.1 Prophylaxis of Organ Rejection in Renal Transplantation Sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. In patients at low- to moderate-immunologic risk, it is recommended that sirolimus be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn 2 to 4 months after transplantation [ see Dosage and Administration (2.2) ]. In patients at high-immunologic risk (defined as Black recipients and/or repeat renal transplant recipients who lost a previous allograft for immunologic reason and/or patients with high panel-reactive antibodies [PRA; peak PRA level >80%]), it is recommended that sirolimus be used in combination with cyclosporine and corticosteroids for the first year following transplantation [ see Dosage and Administration (2.3) , Clinical Studies (14.3) ]. 1.2 Limitations of Use in Renal Transplantation Cyclosporine withdrawal has not been studied in patients with Banff Grade 3 acute rejection or vascular rejection prior to cyclosporine withdrawal, those who...

Mechanism: Sirolimus inhibits T-lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin [IL]-2, IL-4, and IL-15) stimulation by a mechanism that is distinct from that of other immunosuppressants. Sirolimus also inhibits antibody production. In cells, sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex. The sirolimus:FKBP-12 complex has no effect on calcineurin activity. This complex binds to and inhibits the activation of the mammalian target of rapamycin (mTOR), a key regulatory kinase. This...

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 28, 2015 Supplement 73 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
  • Jan 14, 2008 Supplement 43 · Efficacy LetterLabel
  • Jan 30, 2007 Supplement 37 · Efficacy Letter
  • Jun 2, 2006 Supplement 32 · Efficacy LetterLabel
  • Mar 11, 2005 Supplement 24 · Efficacy · priority review LetterLabel
  • Apr 11, 2003 Supplement 4 · Efficacy ReviewLetterLabel
  • Aug 25, 2000 Original approval · Type 3 - New Dosage Form OrphanReviewLetterLabel
4 products under this application
  • RAPAMUNE · SIROLIMUS 0.5MG · TABLET, ORAL · Prescription · TE AB
  • RAPAMUNE · SIROLIMUS 2MG · TABLET, ORAL · Prescription · TE AB
  • RAPAMUNE · SIROLIMUS 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
  • RAPAMUNE · SIROLIMUS 1MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Sirolimus" as an intervention, any sponsor and status, largest first.

All 1,853 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use2,076
  • drug ineffective1,139
  • product use in unapproved indication786
  • pyrexia531
  • diarrhoea529
  • pneumonia500
  • drug interaction450
  • acute kidney injury443
  • thrombotic microangiopathy386
  • transplant rejection384
  • cytomegalovirus infection355
  • condition aggravated317

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200441
200553
200651
2007232
2008194
2009294
2010152
2011253
2012231
2013204
2014239
2015315
2016425
2017598
2018845
2019990
20201,021
20211,054
20221,230
20231,128
20241,437
20251,502
2026988

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Rapamune (Sirolimus)

2024 spending

$224K

Beneficiaries

53

150 claims

Per beneficiary

$4,226

$26.33 per unit

View as table
YearSpending
2020$1,758,753
2021$1,180,014
2022$887,975
2023$759,583
2024$223,979

Part B: Rapamune* (Sirolimus*) · HCPCS J7520

2024 spending

$4.4M

Beneficiaries

6,016

52,678 claims

Per beneficiary

$729

2024 ASP limit $1.95 per unit

View as table
YearSpending
2020$17,028,532
2021$14,674,103
2022$8,531,371
2023$7,242,547
2024$4,386,016

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,789 on PubMed

Sponsor: Pf Prism Cv

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.